Tagged with M

France France is betting big on industrial transformation. With its sweeping EUR 54 billion France 2030 investment plan, the government has laid down a clear ambition: to become a global leader in innovation and industrial competitiveness. While foreign investment is flowing in, and biomedicine production is robust, local pharma industry leaders…

Americas In a world where medical innovation is accelerating, Latin America–a region of some 662 million people—is falling dangerously behind. Patients face wait times of up to 5.6 years to access life-saving therapies already available elsewhere. This is not merely a delay, but a systemic failure rooted in chronic underinvestment and…

Denmark At first glance, Denmark might seem an unlikely hub for pharmaceutical production. With its small size and some of the highest labour costs in Europe, manufacturers might decide to look elsewhere. Yet major global players like Fujifilm Biotechnologies and AGC Biologics are doubling down on their Danish investments, expanding facilities…

Denmark Morten Graugaard, former partner at Novo Holdings A/S, a global life science investment fund, became CEO of Orbis Medicine in February 2025. Drawing on his deep experience in life sciences and venture capital, he has led the company to raise EUR 116 million in funding, positioning Orbis as a pioneer…

Denmark Leading GN’s Hearing division with over a decade of insight and hands-on experience, Peter Justesen has overseen the company’s evolution into a more integrated, globally attuned, and innovation-led organisation. In this conversation, he reflects on the group’s transformation, the technological frontiers of hearing care, and the urgency of reframing hearing…

Denmark After years abroad, Radiometer’s President and CEO, Francis Van Parys, returned to Europe to lead one of Denmark’s most historic MedTech companies into its next chapter. In this interview, he discusses how Radiometer is redefining its role, moving beyond instrumentation to become a driver of time-sensitive clinical decisions through digital…

Switzerland Pharmaceutical manufacturing is evolving into a strategic pillar of competitiveness, shaped by modular design, digital integration, and a growing focus on long-term efficiency. Bilfinger, through its Technology segment, is playing a central role in this transformation, supporting clients across biopharma, energy transition, and nuclear with scalable, future-ready solutions. In this…

Colombia Clara Isabel Rodríguez, Executive Director of the Colombian Association of the Pharmaceutical Industry (ASCIF), shares her journey from public sector leadership to industry advocacy. With deep experience in health regulation and public administration, Rodríguez reflects on Colombia’s pharma landscape, the challenges of ongoing health reform, and why local manufacturing is…

Brazil Brazil’s pharmaceutical sector is undergoing a quiet but significant transformation. Once dominated by multinationals and focused largely on generics, a group of leading domestic players is now charting a different course, towards innovation, manufacturing sovereignty, and strategic influence. Speaking on behalf of Grupo FarmaBrasil, a coalition of the country’s top…

LatAm Yaneth Giha, Executive Director of FIFARMA, has transformed the organisation from a traditional trade association into a strategic platform for advancing healthcare access in Latin America. The first woman to lead FIFARMA, she drives evidence-based solutions, multi-stakeholder collaboration, and regulatory reform, positioning the region as a rising force in global…

Global Whether in the corridors of the FDA or the fast-evolving frameworks of ANVISA in Brazil, regulators around the world are undergoing a quiet revolution. While mature markets like the US and Europe double down on digitalisation and real-world evidence, emerging players like Brazil and China are accelerating access and joining…

Denmark As European biotech continues to navigate tightening capital markets and increasing global competition, Kurma Partners is doubling down on its core belief: that world-class innovation can, and should, be built and scaled from within Europe. Managing Partner Rémi Droller shares how Kurma’s investment model combines early-stage company creation with long-term…